Kathleen Fanning is President and Chief Executive Officer of Mozart Therapeutics, a private Seattle based biopharmaceutical company focused on the development of novel CD8 T cell immune modulators in autoimmune disease. Ms. Fanning has over 35 years of industry experience holding previous leadership roles in both public and private biopharmaceutical companies. Prior to Mozart she served as President and CEO at Nohla Therapeutics; a private cell therapy company. During her tenure at Nohla she provided strategic and operational leadership to quickly transition the company from an academic focus to a fully integrated operating business. Prior to joining Nohla, Ms. Fanning was Chief Operating Officer at VentiRx where she was instrumental in the strategic collaboration with Celgene. She has held senior leadership roles at Cell Therapeutics Inc., and CellPro Inc. that included Vice President of Business Development and Vice President of Sales and Marketing where she built and led global sales and marketing organizations. Earlier in her career she spent 13 years at Zeneca Pharmaceuticals (now AstraZeneca) holding positions of ascending responsibility in sales, marketing and early commercial development. Ms. Fanning received her B.A. in Zoology from Miami University in Oxford, Ohio. She is also a director of Egenesis Bio.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Walden Biosciences
Walden Biosciences is a biotechnology company relentlessly focused on developing first-in-class, highly-targeted therapies for individuals living with kidney disease. We are developing breakthrough medicines targeted directly to the kidney and will be successful through our comprehensive knowledge and understanding of novel kidney-specific biological pathways and our team’s track record in drug discovery. Our goal is to transform the treatment of kidney disease by reversing its progression, enabling and inspiring patients to resume their normal lives. Our culture is collaborative and entrepreneurial, and our team is dynamic and driven by data and innovation. We want to make the best decisions with the best available information, lead by example, and bring transformative medicines to patients in need. Walden is based in the heart of Cambridge, MA between Harvard, Massachusetts Institute of Technology (MIT), and Massachusetts General Hospital.